ArticleJournal of gastroenterology2026
Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe potential for recompensation and its defining criteria in patients with decompensated cirrhosis due to primary biliary cholangitis (PBC) remain poorly defined. Therefore, our study aimed to explore the criteria for etiological suppression and provide preliminary insights into PBC recompensation.
methodsIn this retrospective-prospective study, we enrolled hospitalized patients with PBC cirrhosis from January 2014 to June 2023. Recompensation was defined according to the Baveno VII criteria. In addition, expanded recompensation criteria were evaluated for patients on low-dose diuretics and/or lactulose/rifaximin with resolution of decompensation and stable improvement of liver function. We explored whether the biochemical responses to UDCA could serve as surrogates for etiological suppression.
resultsWe enrolled 240 patients with PBC cirrhosis (122 compensated and 118 decompensated). With a median follow-up of 50.0 (31.0, 72.0) months, 18 (15.3%) out of 118 decompensated patients achieved recompensation and 31 (26.3%) achieved the expanded recompensation. Both recompensated and expanded recompensated patients showed similar long-term outcomes to compensated patients (recompensation: hazard ratio [HR]: 0.70, p = 0.735; expanded recompensation: HR: 0.83, p = 0.814). Patients with variceal hemorrhage as index decompensation had higher potential of recompensation. Fulfillment of the Paris II and Momah/Lindor criteria was linked to better further decompensation-free survival and long-term stabilization of liver function reserve.
conclusionRegression to a recompensated stage is possible in PBC patients with decompensated cirrhosis, especially when portal hypertension is the main driver of index decompensation. The Paris II and Momah/Lindor criteria are potentially useful as surrogate indicators for etiological suppression.
Indexed as
Identifiers
41528438What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.